The Therapeutic Effect of Getong Tongluo Capsule Combined with Butylphthalide in the Treatment of Acute Posterior Circulation Infarction and its Effect on Serum TGF-β1/Smad3 Signaling Pathway and Platelet Related Factors
[Objective]To explore the therapeutic effect of Getong Tongluo capsule combined with butylphthalide in the treatment of in posterior circulation infarction(POCI),and its effects on the serum transforming growth factor-β1(TGF-β1)/Smad3 signaling pathway and platelet related factors.[Methods]A retrospective analysis was conducted on the clinical data of 114 POCI patients admitted to our hospital from January 2020 to January 2023.According to different treatment methods,they were divided into the observation group and the control group,with 57 cases in each group.The control group was treated with butylphthalide,while the observation group was treated with Getong Tongluo capsules and butylphthalide.Two groups were compared in terms of efficacy,National Institute of Health stroke scale(NIHSS),Bar-thel index,serum TGF-β1/Smad3 signaling pathway related protein expression(Smad3,TGF-β1,Smad1),platelet relat-ed factors[vascular endothelial growth factor(VEGF),platelet activating factor(PAF),angiotensin Ⅱ(Ang Ⅱ),matrix metalloproteinase-9(MMP-9)],inflammatory response indicators[soluble tumor necrosis factor related apoptosis indu-cing ligand(sTRAIL),hypersensitive C-reactive protein(hs-CRP),monocyte chemotactic protein-1(MCP-1)].[Re-sults]The effective rate of the observation group was 94.74％(54/57),which was higher than the control group's 80.70％(46/57),and the difference was statistically significant(x2=5.211,P=0.022).After treatment,the NIHSS scores in both groups were lower than before treatment,and the observation group was lower than the control group.The Barthel index score was higher than that before treatment,and the observation group was higher than the control group(P＜0.05).After treatment,Smad3,TGF-β1 and Smad1 of the two groups were lower than those before treatment,and the observation group was lower than the control group(P＜0.05).After treatment,the serum VEGF levels in both groups were higher than those before treatment,and the observation group was higher than the control group.The level of the serum PAF,Ang Ⅱ and MMP-9 was lower than those before treatment,and the observation group was lower than the control group(P＜0.05).After treatment,the levels of serum hs-CRP,sTRAIL and MCP-1 of the two groups were lower than those before treatment,and the observation group was lower than the control group(P＜0.05).[Conclusion]The combination of Getong Tongluo capsules and butylphthalide can inhibit the expression of TGF-β1/Smad3 signaling pathway related proteins,inhibit platelet activation,alleviate inflammatory response,and improve patient neurological function.
万方数据
维普
